Zymeworks Inc. (ZYME)
NASDAQ: ZYMEHealth CareBiotechnology: Pharmaceutical PreparationsUSD
At close: Oct 7, 4:00 PM ET · Delayed 15 min
ZYME stock chart
Technical analysisKey statistics
All statistics- Market cap
- $1.90B
- Forward P/E
- 30.43
- EPS (TTM)
- -$2.02
- Dividend yield
- None
- 52-week range
- 16.00 – 31.34
- Day range
- 25.17 – 27.01
- Volume / Avg
- 1.20M / 673.06K
- Beta
- —
- Shares outstanding
- 71.20M
- Next earnings
- Nov 5, 2026
52-week range
ZYME stock today
On Oct 7, ZYME ended the session at $26.53, adding $0.88 (3.43%), versus the S&P 500's 0.22% decline. Shares are 15.3% below their 52-week high of $31.34, set on Sep 3, 2026 and 65.8% above the 52-week low of $16.00, in the middle of the past year's range. ZYME is up 0.8% year to date, underperforming the S&P 500 (+14.0%). Over the past 12 months, the stock has gained 60.8%.
Zymeworks has posted a net loss over the last twelve months (EPS of -$2.02), so its P/E ratio is not meaningful. Zymeworks's next earnings report is expected on Nov 5, 2026.
Summary generated from market data by MetaCap's automated system. Methodology
About Zymeworks
Company profileZymeworks Inc., a biotechnology company, develops biotherapeutics for the treatment of cancer, inflammation, and autoimmune diseases. The company's platforms include Azymetric multispecific antibody platform; Drug Conjugate platform that includes a suite of proprietary cytotoxins comprising topoisomerase and microtubulin inhibiting toxins, stable linkers, and conjugation technologies; EFECT platform, which consists of a set of modifications to the Fc region of antibodies; and ProTECT, a tumor-specific immune co-stimulation platform. Its lead product candidates include Ziihera (zanidatamab-hrii), a bispecific antibody targeting HER2-expressing tumors; zanidatamab for the treatment of neoadjuvant populations, breast cancer, and other HER2-expressing cancers; Pasritamig, a bispecific T cell engager targeting human kallikrein 2 for the treatment monotherapy and castration resistant prostate cancer; ZW191, a clinical- antibody-drug conjugates (ADC) that targets folate receptor alpha expressing tumors, including ovarian, endometrial, and non-small cell lung cancers; ZW251, a clinical-stage ADC molecule for the treatment of glypican 3 expressing hepatocellular carcinoma; ZW220, an ADC that targets NaPi2b-expressing NSCLC and ovarian cancer; ZW209, a novel TriTCE targeting Delta-like ligand 3 -expressing tumor cells for the treatment of solid tumors; and ZW1528, a bispecific molecule to treat chronic obstructive pulmonary disease.
- Sector
- Health Care
- Industry
- Biotechnology: Pharmaceutical Preparations
- CEO
- Mr. Kenneth H. Galbraith C.A.
- Headquarters
- Middletown, DE
- Employees
- 231
- Website
- zymeworks.com
Analyst forecast
ForecastConsensus (14 analysts)
strong_buy
Avg. price target
$41.21+55.33%
- Strong buy 2
- Buy 12
- Hold 0
- Sell 0
- Strong sell 0
Target range
Ratings and targets reflect third-party analyst opinions, not MetaCap recommendations.
Earnings
Earnings history- Next report
- Nov 5, 2026
- EPS estimate
- $2.50
Zymeworks peers
Health Care sector| Company | Price | % Chg | Market cap | Compare |
|---|---|---|---|---|
| GPCRStructure Therapeutics Inc. ADR | 26.68 | -2.88% | $1.90B | vs ZYME |
| AGIOAgios Pharmaceuticals Inc. | 31.79 | +0.22% | $1.90B | vs ZYME |
| PVLAPalvella Therapeutics Inc. | 130.59 | +2.02% | $1.88B | vs ZYME |
| TRVITrevi Therapeutics Inc. | 13.14 | -0.30% | $1.87B | vs ZYME |
| MLYSMineralys Therapeutics Inc. | 22.09 | +0.64% | $1.95B | vs ZYME |
| ADRXADARx Pharmaceuticals Inc. | 17.33 | -6.73% | $1.85B | vs ZYME |
| SRPTSarepta Therapeutics Inc. | 17.50 | +1.10% | $1.85B | vs ZYME |
| XERSXeris Biopharma Holdings Inc. | 10.11 | +0.40% | $1.84B | vs ZYME |
Indexes, lists and sector
Zymeworks stock FAQ
What is Zymeworks's stock price today?
ZYME last traded at $26.53 as of Oct 7, 4:00 PM EDT, up 3.43% on the day. Prices are delayed at least 15 minutes.
When is Zymeworks's next earnings date?
Zymeworks is expected to report earnings on Thursday, November 5, 2026. Analysts expect EPS of $2.50.
Who is Zymeworks's CEO?
Mr. Kenneth H. Galbraith C.A. is the chief executive officer of Zymeworks Inc., which has about 231 employees.
What is the ZYME 52-week high?
The 52-week high for ZYME is $31.34 and the 52-week low is $16.00. The stock is currently 15.3% below its high.